The present observations demonstrate clinical relevance as they suggest that β2AR selective-agonist therapy intended to alleviate signs and symptoms of pulmonary dysfunction in CF may be contraindicated in certain individuals. The gene discussed is ADRB2; the disease is cystic fibrosis.